135 related articles for article (PubMed ID: 16459174)
1. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
Jänne PA
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
[TBL] [Abstract][Full Text] [Related]
2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
3. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
4. An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Edelman MJ
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S3-8. PubMed ID: 16459173
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
6. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
7. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
Agelaki S; Georgoulias V
Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
[TBL] [Abstract][Full Text] [Related]
11. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
12. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
13. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
15. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
Toschi L; Cappuzzo F
Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
Eberhard DA; Giaccone G; Johnson BE;
J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
[TBL] [Abstract][Full Text] [Related]
17. EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giaccone G; Rodriguez JA
Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
19. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
Brachtel EF; Iafrate AJ; Mark EJ; Deshpande V
Diagn Cytopathol; 2007 May; 35(5):257-62. PubMed ID: 17427221
[TBL] [Abstract][Full Text] [Related]
20. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]